PI
LGND icon

Putnam Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Putnam Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$393K Sell
5,503
-144
-3% -$8.5K ﹤0.01% 1007
2023
Q3 		$338K Buy
+5,647
New +$372K ﹤0.01% 1036
2020
Q4 		– Sell
-40,436
Closed -$2.4M – 832
2020
Q3 		$2.4M Sell
40,436
-40,663
-50% -$2.77M ﹤0.01% 614
2020
Q2 		$5.66M Buy
81,099
+42,100
+108% +$2.67M 0.01% 447
2020
Q1 		$1.77M Sell
38,999
-21,086
-35% -$1.2M ﹤0.01% 646
2019
Q4 		$3.91M Hold
60,085
– – 0.01% 572
2019
Q3 		$3.73M Sell
60,085
-4,139
-6% -$260K 0.01% 577
2019
Q2 		$4.57M Hold
64,224
– – 0.01% 539
2019
Q1 		$5.04M Sell
64,224
-13,983
-18% -$1.06M 0.01% 506
2018
Q4 		$6.62M Hold
78,207
– – 0.02% 413
2018
Q3 		$13.4M Buy
78,207
+46,004
+143% +$6.94M 0.03% 329
2018
Q2 		$4.16M Sell
32,203
-8,308
-21% -$927K 0.01% 577
2018
Q1 		$4.17M Buy
40,511
+9,049
+29% +$895K 0.01% 547
2017
Q4 		$2.69M Sell
31,462
-233
-0.7% -$20.2K 0.01% 686
2017
Q3 		$2.69M Buy
+31,695
New +$2.51M 0.01% 682
2017
Q2 		– Sell
-21,942
Closed -$1.45M – 1208
2017
Q1 		$1.45M Sell
21,942
-2,622
-11% -$172K ﹤0.01% 924
2016
Q4 		$1.56M Sell
24,564
-116
-0.5% -$7.32K ﹤0.01% 900
2016
Q3 		$1.57M Sell
24,680
-14,622
-37% -$1.07M ﹤0.01% 910
2016
Q2 		$2.92M Buy
39,302
+14,582
+59% +$1.08M 0.01% 818
2016
Q1 		$1.65M Buy
24,720
+497
+2% +$30.2K ﹤0.01% 994
2015
Q4 		$1.64M Sell
24,223
-524
-2% -$32.4K ﹤0.01% 1027
2015
Q3 		$1.32M Buy
24,747
+718
+3% +$43.6K ﹤0.01% 1099
2015
Q2 		$1.51M Sell
24,029
-123
-0.5% -$6.71K ﹤0.01% 1130
2015
Q1 		$1.16M Buy
+24,152
New +$925K ﹤0.01% 1173

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments's LGND Position: Q4 2023 in Review

Putnam Investments reduced its Ligand Pharmaceuticals (LGND) stake by 2.6% in Q4 2023, selling an estimated $8.5K and leaving 5,503 shares worth $393K. The position accounts for ﹤0.01% of the portfolio, ranked #1007.

Putnam Investments first reported a position in LGND in Q1 2015 and has held it in 24 quarters since. The position peaked at $13.4M in Q3 2018. 211 funds tracked by Wall St. Rank hold LGND as of Q4 2023.

  • Putnam Investments held 5,503 shares of Ligand Pharmaceuticals worth $393K as of Q4 2023.
  • Putnam Investments sold 144 Ligand Pharmaceuticals shares in Q4 2023, an estimated $8.5K.
  • Ligand Pharmaceuticals made up ﹤0.01% of Putnam Investments's portfolio in Q4 2023, its #1007 holding.
  • Putnam Investments first reported a position in Ligand Pharmaceuticals in Q1 2015 and has held it in 24 quarters since.
  • Putnam Investments's Ligand Pharmaceuticals position peaked at $13.4M in Q3 2018.
  • 211 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.